Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142649 | 0.95 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL426304 | 0.95 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL343622 | 0.95 | TSHR (0.38) | TSHRCYP2C19 | |
| SCHEMBL24270894 | 0.90 | — | — | |
| SCHEMBL2123607 | 0.78 | — | — | |
| SCHEMBL19257774 | 0.73 | — | — | |
| SCHEMBL15937108 | 0.72 | GRIN2D (0.46) | TSHR | |
| SCHEMBL503235 | 0.70 | — | — | |
| SCHEMBL1766154 | 0.70 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL10882932 | 0.68 | TSHR (0.33) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560366-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-24 | — | — | US | disclosed |
| EP-4048662-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021081074-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115010-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115010-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK2 | TSHR 3681/4885CYP2C19 4476/4885 |
| US-11560366-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | CLK1, MAP3K12, CLK2 | TSHR 3681/4885CYP2C19 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.